Lactobacillus plantarum strain 299(Lactobacillus plantarum strain 299) - 在研适应症：急性移植物抗宿主病，白血病，淋巴瘤_专利_临床

概要

基本信息

药物类型

益生菌

别名

靶点-

作用机制

细菌替代物、微生物调节剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

急性移植物抗宿主病白血病淋巴瘤+ [1]

非在研适应症-

原研机构

National Cancer Institute

在研机构

National Cancer Institute

The Children's Oncology Group Foundation, Inc.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 Lactobacillus plantarum strain 299 相关的临床试验

ChiCTR2300077434 / Suspended早期临床1期IIT

Intervention of Lactobacillus animalis and Lactobacillus plantarum in adjuvant treatment of recurrent respiratory tract infections in children

开始日期2023-11-09

申办/合作机构-

ChiCTR2300075360 / Suspended临床1期IIT

Clinical study on the application of Lactobacillus plantarum in patients with functional constipation

开始日期2023-09-01

申办/合作机构-

NCT03057054 / Active, not recruiting临床3期IIT

The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

This randomized phase III trial studies how well Lactobacillus plantarum works in preventing acute graft versus host disease in children undergoing donor stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease in children, adolescents, and young adults undergoing donor stem cell transplant.

开始日期2018-04-30

申办/合作机构

The Children's Oncology Group Foundation, Inc.

[+1]

100 项与 Lactobacillus plantarum strain 299 相关的临床结果

登录后查看更多信息

100 项与 Lactobacillus plantarum strain 299 相关的转化医学

登录后查看更多信息

100 项与 Lactobacillus plantarum strain 299 相关的专利（医药）

登录后查看更多信息

82

项与 Lactobacillus plantarum strain 299 相关的文献（医药）

2025-01-01·Journal of Affective Disorders

Probiotic Lactobacillus plantarum 299v supplementation in patients with major depression in a double-blind, randomized, placebo-controlled trial: A metabolomics study

Article

作者: Godzien, Joanna ; Waszkiewicz, Napoleon ; Lopez-Gonzalvez, Angeles ; Szulc, Agata ; Ostrowska, Lucyna ; Barbas-Bernardos, Cecilia ; Barbas, Coral ; Swieton, Justyna ; García, Antonia ; Bernardos, Cecilia Barbas ; Kalaska, Bartlomiej ; Ciborowski, Michal ; Kretowski, Adam ; Rudzki, Leszek ; Pawlak, Dariusz

BACKGROUNDUnderstanding the multifactorial nature of major depressive disorder (MDD) is crucial for tailoring treatments. However, the complex interplay of various factors underlying the development and progression of MDD poses significant challenges. Our previous study demonstrated improvements in cognitive functions in MDD patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) supplemented with Lactobacillus plantarum 299v (LP299v).METHODSTo elucidate the biochemical mechanisms underlying cognitive functions improvements, we explored underlying metabolic changes. We employed multi-platform metabolomics, including LC-QTOF-MS and CE-TOF-MS profiling, alongside chiral LC-QqQ-MS analysis for amino acids.RESULTSSupplementation of SSRI treatment with LP299v intensified the reduction of long-chain acylcarnitines, potentially indicating improved mitochondrial function. LP299v supplementation reduced N-acyl taurines more than four times compared to the placebo, suggesting a substantial impact on restoring biochemical balance. The LP299v-supplemented group showed increased levels of oxidized glycerophosphocholine (oxPC). Additionally, LP299v supplementation led to higher levels of sphingomyelins, L-histidine, D-valine, and p-cresol.LIMITATIONSThis exploratory study suggests potential metabolic pathways influenced by LP299v supplementation. However, the need for further research hinders the ability to draw definitive conclusions.CONCLUSIONSObserved metabolic changes were linked to mitochondrial dysfunction, inflammation, oxidative stress, and gut microbiota disruption. Despite the subtle nature of this alterations, our research successfully detected these differences and connected them to the metabolic disruptions associated with MDD. Our findings emphasise the intricate relationship between metabolism, gut microbiota, and mental health prompting further research into the mechanisms of action of probiotics in MDD treatment.

2024-08-01·Food Chemistry

Production of prebiotic enriched maple syrup through enzymatic conversion of sucrose into fructo-oligosaccharides

Article

作者: Simović, Milica ; Milivojević, Ana ; Veljković, Milica ; Banjanac, Katarina ; Bezbradica, Dejan ; Ćorović, Marija

Maple syrup, a popular natural sweetener has a high content of sucrose, whose consumption is linked to different health issues such as obesity and diabetes. Hence, within this paper, the conversion of sucrose to prebiotics (fructo-oligosaccharides, FOS) was proposed as a promising approach to obtaining a healthier, value-added product. Enzymatic conversion was optimized with respect to key experimental factors, and thereafter derived immobilized preparation of fructosyltransferase (FTase) from Pectinex® Ultra SP-L (FTase-epoxy Purolite, 255 IU/g support) was successfully utilized to produce novel functional product in ten consecutive reaction cycles. The product, obtained under optimal conditions (60 °C, 7.65 IU/mL, 12 h), resulted in 56.0% FOS, 16.7% sucrose, and 27.3% monosaccharides of total carbohydrates, leading to a 1.6-fold reduction in caloric content. The obtained products` prebiotic potential toward the probiotic strain Lactobacillus plantarum 299v was demonstrated. The changes in physico-chemical and sensorial characteristics were esteemed as negligible.

2023-11-01·Gastroenterology

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Review

作者: Khasawneh, Mais ; Moayyedi, Paul ; Black, Christopher J ; Goodoory, Vivek C ; Ford, Alexander C ; Quigley, Eamonn M M

BACKGROUND & AIMSSome probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.METHODSMEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.RESULTSWe identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.CONCLUSIONSSome combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.

100 项与 Lactobacillus plantarum strain 299 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性移植物抗宿主病	临床3期	美国	National Cancer Institute	2018-04-30
急性移植物抗宿主病	临床3期	加拿大	National Cancer Institute	2018-04-30
白血病	临床3期	加拿大	National Cancer Institute	2018-04-30
白血病	临床3期	美国	National Cancer Institute	2018-04-30
淋巴瘤	临床3期	美国	National Cancer Institute	2018-04-30
淋巴瘤	临床3期	加拿大	National Cancer Institute	2018-04-30
移植物抗宿主病	临床3期	-	The Children's Oncology Group Foundation, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03057054 (CTgov)	临床3期	急性移植物抗宿主病 \| 白血病 \| 淋巴瘤	173	Allogeneic Hematopoietic Stem Cell Transplantation+Lactobacillus plantarum strain 299v (Arm I (Lactobacillus Plantarum, alloHCT))	窪築繭築製鬱窪築廠觸(觸積構醖鹽憲觸艱餘淵) = 廠鬱鑰鹽窪製憲憲積憲鏇膚鏇鹽簾網蓋壓網選 (艱醖鏇積觸顧夢憲遞餘, 夢簾顧醖憲鏇鹹襯鏇膚 ~ 鹹築遞憲齋選製願遞衊) 更多	-	2023-07-17
				Allogeneic Hematopoietic Stem Cell Transplantation (Arm II (Placebo, alloHCT))	窪築繭築製鬱窪築廠觸(觸積構醖鹽憲觸艱餘淵) = 襯獵築醖蓋夢製餘選糧鏇膚鏇鹽簾網蓋壓網選 (艱醖鏇積觸顧夢憲遞餘, 積製構糧壓窪淵繭襯窪 ~ 壓窪積膚獵選鬱廠艱窪) 更多